Alignment Healthcare reported third-quarter 2026 revenue of $1.4 billion and adjusted EBITDA of $22 million, lowering full-year 2026 guidance to adjusted gross profit of no less than $575 million and adjusted EBITDA of no less than $100 million amid elevated medical costs.
ALHC · Alignment Healthcare, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Alignment Healthcare reported Health Plan membership of 301,200 at September 30, 2026, up 31.2% from a year earlier. For the three months ended September 30, 2026, revenue was 1,358,290 and net loss was 8,052, in thousands of dollars.
Alignment Healthcare, Inc. reported third-quarter revenue of $1,358.3 million, up 36.7% year-over-year, and health plan membership of approximately 301,200, up 31.2%. It lowered fiscal-year 2026 adjusted gross profit and adjusted EBITDA guidance due to higher medical costs.
Alignment Healthcare expects California HMO health plan contract H3815 to have a 3.5-Star Rating for rating year 2027, down from 4.0-Star Rating for rating year 2026; the change will affect fiscal year 2028 quality bonus payments.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Oct 29, 2026TL;DR. Growth remained strong, with revenue up 36.7%, membership up 31.2%, adjusted gross profit up 11.6%, improved operating efficiency, strong cash generation, raised full-year membership and revenue guidance, and management targeting at least 20% top-line growth in 2027. However, higher medical costs, a 3.5-star California HMO rating, and weaker quarterly profitability pressured results, prompting lower full-year profit guidance and negative fourth-quarter adjusted EBITDA guidance.
- + Third-quarter revenue increased 36.7% year-over-year to $1,358.3 million.
- + Health plan membership increased 31.2% year-over-year to approximately 301,200 members.
- + Adjusted FG&A was 8.9% of revenue, improving 70 basis points year-over-year and outperforming the guidance midpoint by approximately 90 basis points.
- + The company generated $158 million of operating cash flow during the first nine months and described its liquidity profile as strong.
- + Management said it remained positioned to target at least 20% top-line growth in 2027 based on early AEP results.
- + Full-year 2026 membership and revenue guidance was raised to reflect continued sales momentum.
- − Full-year 2026 adjusted gross profit and adjusted EBITDA guidance was lowered.
- − The adjusted medical benefits ratio increased approximately 240 basis points year-over-year to 89.5%, reflecting elevated appeals and disputes and higher catastrophic-case and skilled-nursing costs.
- − Adjusted EBITDA declined 32.8% year-over-year to $21.8 million, and the company reported a net loss of $8.1 million.
- − The California HMO contract earned a 3.5-star rating, below management's expectations.
- − Fourth-quarter guidance called for adjusted EBITDA of no less than negative $28 million.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $68.1M | Q2 FY2026 | — |
GAAP → non-GAAP reconciliationGAAP Net income 36.56M
+0K Net loss attributable to noncontrolling interest
+4.28M Interest expense
+7.86M Depreciation and amortization
+1.27M Income tax expense
+18.17M Equity-based compensation
+14K Litigation costs
-1K Gain on sale of property and equipment
= Adjusted EBITDA 68.15M
|
|||
| Adjusted EBITDA margin non-GAAP | 5.1% | Q2 FY2026 | — |
| Adjusted gross profit non-GAAP | $182.9M | Q2 FY2026 | — |
GAAP → non-GAAP reconciliationGAAP Income from operations 42.1M
+1.89M Equity-based compensation (medical expenses)
+3K Depreciation (medical expenses)
+7.85M Depreciation and amortization
+131M Selling, general, and administrative expenses
= Adjusted Gross Profit 182.85M
|
|||
| Health plan membership | 294,100 | Q2 FY2026 | — |
| Medical benefits ratio | 86.3% | Three Months Ended June 30, 2026 filing | — |
| Medical benefits ratio based on adjusted gross profit non-GAAP | 86.3% | Q2 FY2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Healthcare Plans — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALHC
this stock
Alignment Healthcare, Inc.
|
$1.54B | -62.7% | +46.1% | — | 11.1% |
|
UNH
Unitedhealth Group Inc
|
$365.09B | +23.4% | +11.8% | 23.3 | 1.6% |
|
CVS
CVS HEALTH Corp
|
$114.32B | +12.6% | +7.8% | 10.4 | 1.4% |
|
ELV
Elevance Health, Inc.
|
$92.84B | +22.6% | +12.5% | 18.3 | 2.1% |
|
CI
Cigna Group
|
$78.26B | +7.9% | +11.2% | 13.1 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 29, 2026
- This year
- 23
Alignment Healthcare, Inc. reported third-quarter revenue of $1,358.3 million, up 36.7% year-over-year, and health plan membership of approximately 301,200, up 31.2%. It lowered fiscal-year 2026 adjusted gross profit and adjusted EBITDA guidance due to higher medical costs.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALHC | +0.3% | -11.1% | -54.1% | +1.2% | -62.7% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -2.3% | -10.0% | -54.6% | +1.4% | -73.4% |